<DOC>
	<DOC>NCT02504008</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in patients with CRPS-I.</brief_summary>
	<brief_title>CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Key Male or female of at least 18 years of age Recently confirmed diagnosis of CRPS1 (Budapest criteria) Average pain intensity score of â‰¥ 5 (based on an 11point scale [0 10]) Willing and able to provide written informed consent Key Received chronic opioid therapy within 4 weeks Received a sympathetic nerve block within 3 weeks Active litigation or a pending workers' compensation decision Any other clinically significant medical or pain condition (eg, Parkinson's disease, cognitive impairment, or fibromyalgia) or clinical laboratory abnormality that would in the investigator's judgment interfere with the subject's ability to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>bisphosphonate</keyword>
	<keyword>CRPS</keyword>
	<keyword>RSD</keyword>
	<keyword>non-opioid</keyword>
	<keyword>CRPS-1</keyword>
	<keyword>acute on chronic pain</keyword>
	<keyword>chronic pain</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>